Immuneering Corporation (IMRX) NASDAQ
5.57
+0.505(+9.98%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
5.57
+0.505(+9.98%)
Currency In USD
| Previous Close | 5.06 |
| Open | 5.17 |
| Day High | 5.58 |
| Day Low | 5.06 |
| 52-Week High | 10.08 |
| 52-Week Low | 1.63 |
| Volume | 1.47M |
| Average Volume | 1.11M |
| Market Cap | 202.02M |
| PE | -5.25 |
| EPS | -1.06 |
| Moving Average 50 Days | 5.32 |
| Moving Average 200 Days | 5.8 |
| Change | 0.51 |
Immuneering to Present at the Leerink Global Healthcare Conference
GlobeNewswire Inc.
Mar 02, 2026 9:05 PM GMT
NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management will present at the Leerin
Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Feb 18, 2026 9:05 PM GMT
NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management will present at the Oppenhe
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
GlobeNewswire Inc.
Jan 07, 2026 9:00 PM GMT
- Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard of care gemcitabine/nab-paclitaxel (GnP) - - Atebimetinib consistently demonstrates impressive overall survival advantage